First-in-human phase 1 placebo-controlled single-ascending-dose study in 26 healthy adults: Fc-modified anti-CD154 antibody TNX-1500 (3 to 30 mg/kg IV) was generally well tolerated, with no thromboembolic events and a mean half-life of 33.8 to 37.8 days.
RCTn = 26
Lederman et al. First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults